Dipeptidyl-peptidase 4 inhibition: Linking metabolic control to cardiovascular protection

Current Pharmaceutical Design

Volumn 20, Issue 14, 2014, Pages 2387-2394

  Avogaro, Angelo ^a   de Kreutzenberg, Saula ^a   Fadini, Gianpaolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cardiovascular system; Diabetes mellitus; Dipeptidyl peptidases; Incretins

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; ANTIDIABETIC AGENT; CARDIOTONIC AGENT;

ARTICLE; ATHEROGENESIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; GLYCEMIC CONTROL; HEART INFARCTION; HEART PROTECTION; HUMAN; INFLAMMATION; METABOLIC REGULATION; MICROANGIOPATHY; NONHUMAN; PRIORITY JOURNAL; STEM CELL; ANIMAL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; METABOLISM;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84903736092     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990474     Document Type: Article

References (80)

1. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clinical Science 2005; 108: 277-92.
2. Marguet D, Baggio L, Kobayashi T, et. al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. PNAS 2000; 97: 6874-79.
3. Drucker DJ. Dipeptidyl peptidase-4 inhibitors and the treatment of type 2 diabetes. Diabetes Care 2007; 30: 1335-43.
4. Mannucci E, Pala L, Ciani S. et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168-72.
5. Pala L, Pezzatini A, Dicembrini I, et al. Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetol DOI 10.1007/s00592-010-0195-3
6. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1 based therapies and cardiovascular disease: looking beyond glycemic control. Diabetes Obes Metab 2011; 13: 302-12.
7. Matsubara J, Sugiyama S, Sugamura K, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein Edeficient mice. J Am Coll Cardiol 2012; 59: 265-76.
8. Liu L, Liu J, Wong WTR. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like Peptide 1-dependent mechanism. Hypertension 2012; 60: 833-41.
9. Mason P, Jacob RF, Kubant R, et al. Effect of Enhanced Glycemic Control with Saxagliptin on Endothelial Nitric Oxide Release and CD40 Levels in Obese Rats. J Atheroscler Thromb 2011; 18: 774-83.
10. Vittone F, Liberman A, Vasic D. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe-/-mice. Diabetologia 2012; 55: 2267-75.
11. Van Poppel PCM, Smits P, Netea M, Tack CE. Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes. Diabetes Care 2011; 34: 2072-77.
12. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010;106:842-53.
13. Matsui T, Nishino Y, Takeuchi M, Yamagishi S. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res. 2011; 63: 383-388.
14. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res. 2011 Sep;43(10):731-4.
15. Maeda S, Matsui T, Yamagishi S. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol 2012; 158:171-172.
16. Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacologic inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after acute myocardial infarction in mice. Diabetes 2010; 59: 1063-73.
17. Huisamen B, Genis A, Marais E, et al. Pretreatment with DPP-4 inhibitor is infarct sparing in hearts from obese, prediabetic rats. Cardiovasc Drugs Ther 2011; 25: 13-20.
18. Chinda K, Palee S, Surinkaew S, et al. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol 2012; doi:10.1016/j.ijcard.2012.01.011
19. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 2012, doi:10.1016/j.ijcard.2011.12.007.
20. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKAdependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010; 298: H1454-H1465.
21. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardivasc Imaging 2010; 3: 195-201.
22. Theiss HD, Brenner C, Engelman MG, et al. Safety and efficacy of SITAgliptin plus Granulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)-rationale, design and first analysis. Int J Cardiol 2010; 145: 282-84.
23. Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus. Am J Cardiol 2012 Jun 14. [Epub ahead of print]
24. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Current Medical Research & Opinion 2011; 27 S3: 57-64.
25. Bouchard L, Faucher G, Tchernof A, et al. Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals. Acta Diabetol 2009; 46: 13-21.
26. Witteles RM, Visith Keu K, et al. Dipeptidyl Peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyoptahy. J. Card Fail 2012; 18: 804-809.
27. Kos K, Baker AR, Jernas M, et al. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 2009; 11: 285-92
28. Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008; 57: 190-8.
29. Rosmaninho-Salgado J, Marques AP, Estrada M, et al. Dipeptidylpeptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-expression. Peptides 2012; 37: 49-54.
30. Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients J Clin Endocrinol Metab 2009; 94: 846-52.
31. Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N. Vildagliptin in Adult Rats with Insulin Resistance Induced by a High-Fat Diet. Endocrinology 2012; 153: 3878-85.
32. Kern M, Kloting N, Niessen HG, et al. Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity. PLoS One 2012; 7: e38744.
33. Wasada T, McCorkle K, Harris V, et al. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest 1981; 68: 1106-07.
34. Ebert R, Nauck M, Creutzfeldt W. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm Metab Res 1991; 23: 517-21.
35. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-57.
36. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2011; 13: 366-73.
37. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebocontrolled study. Diabetologia 2012; 55: 915-25.
38. Miura K, Kitahara Y, Yamagishi S. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats. Horm Metab Res. 2010; 42: 731-735
39. Jackson EK, Zhang M, Liu W, Mi Z. Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther 2007; 323: 431-37.
40. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibitionin humans. Hypertension 2010; 56: 728-33.
41. Kirino Y, Sato Y, Kamimoto T, et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. Journal of Endocrinology 2009; 200: 53-61.
42. Girardi AC, Degray BC, Nagy T, Biemesderfer D, Aronson PS. Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem 2001; 276: 46671-77.
43. Tanaka T, Nangaku M, Nishiyama A. The role of incretins in saltsensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. Current Opinion in Nephrology and Hypertension 2011; 20: 476-48.
44. Pacheco BP, Crajoinas RO, Couto GK, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 2011; 29: 520-8.
45. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 2007; 292: R897-R901.
46. Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 30, 50-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007; 49: 1114-19.
47. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48: 592-8.
48. Bergenstal RM, Wysham C, Macconell L, et al. for the DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-9.
49. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010; 33: 1759-65.
50. Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012; 14: 561-7.
51. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol 2012; 16: 11-6.
52. Horie Y, Kanada S, Watada H, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, doubleblind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther 2011; 33: 973-89.
53. Pala L, Mannucci E, Pezzatini A, et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochemical and Biophysical Research Communications 2003; 310: 28-31.
54. Fuchs H, Binder R, Greischel A. Tissue Distribution of the Novel DPP-4 Inhibitor BI 1356 is Dominated by Saturable Binding to its Target in Rats. Biopharm Drug Dispos 2009; 30: 229-40.
55. Mega C, de Lemos ET, Vala H, et al. Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat). Exp Diabetes Res 2011; 2011: 162092.
56. Goncalves A, Leal E, Paiva A, et al. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes, Obesity and Metabolism 2012; 14: 454-63.
57. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
58. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008; 29: 295-301.
59. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome. Diabetes 2011; 60: 1917-25.
60. Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat). Mediators Inflamm 2010; 2010: 592760.
61. Dobrian AD, Ma Q, Lindsay JW, et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 2011; 300: E410-E421.
62. Shirakawa J, Fujii H, Ohnuma K, et al. Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice. Diabetes 2011; 60: 1246-57.
63. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice. J Cardiovasc Pharmacol 2011; 58: 157-66.
64. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis. Circulation 2011; 124: 2338-49.
65. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes. Diabetes Care 2012; 35: 2076-82.
66. Makdissi A, Ghanim H, Vora M, et al. Sitagliptin Exerts an Antinflammatory Action. J Clin Endocrinol Metab 2012 doi: 10.1210/jc.2012-1544.
67. Sato-Asahara N, Sasaki Y, Wada H, et al. A dipeptydil peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism doi:pii: S0026-0495(12)00343-5. 10.1016/j.metabol.2012.09.004.
68. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
69. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45: 1449-57.
70. Fadini GP, Sartore S, Schiavon M, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 2006;49:3075-84.
71. Christopherson KW 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305: 1000-3.
72. Zaruba MM, Theiss HD, Vallaster M, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009; 4: 313-23.
73. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes mellitus. Possible role of stromal derived factor-1{alpha}. Diabetes Care 2010; 33: 1607-09.
74. Shigeta T, Aoyama M, Bando YK, et al. Dipeptydil petidase-4 modulates left ventricular dysfunction in cheronic heart failure via angiogenesis-dependent and-independent actions. Circulation 2012; 126: 1838-1851.
75. Jungraithmayr W, De Meester I, Matheeussen V, et al. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg 2012; 41: 1166-73.
76. Huang CY, Shih CM, Tsao NW, et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol 2012 doi: 10.1111/j.1476-5381.2012.02102.x.
77. Marchetti C, Di Carlo A, Facchiano F, et al. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia 2012; 55: 236-44.
78. Broxmeyer HE, Hoggatt J, O'Leary HA, et al. Dipeptydilpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoyesis. Nat Med 2012 doi: 10.1038/nm.2991.
79. Fadini GP, Albiero M, Vigili de Kreutzenberg S, et al. Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans. Diabetes Care 2012 Oct 30. [Epub ahead of print].
80. Fadini GP, Albiero M, Seeger F, et al. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic Res Cardiol 2013 doi: 10.1007/s00395-012-0313-1.